Demand for vitamins has rebounded year-on-year. Tianxin Pharmaceutical states that changes in supply and demand have caused the price of folic acid to rise | Highlights from the earnings conference.

① The general manager of Tianxin Pharmaceutical, Yu Xiaobing, stated that there are signs of recovery in the vitamin market demand year-on-year in the second half of this year, and the changes in market supply and demand have led to an increase in the price of folic acid; ② The secretary of the board of directors of Tianxin Pharmaceutical, Dong Yi, answered questions regarding the fundraising projects.

cls.cnDec 3, 2024 04:45 ET

Tasly Pharmaceutical Group: Some products are priced down, leading to a decrease in Q3 gross margin. All parties are actively promoting the trade with China Resources Sanjiu Medical & Pharmaceutical | Straight to the earnings conference

① Due to the overall low prosperity in the pharmaceutical commerce industry, the company's revenue in this sector declined in the third quarter of this year; although revenue in the pharmaceutical industry sector grew year-on-year, the price reduction of some products led to a decrease in gross margin, and the company expects that the gross margin may remain stable in the future. ② Regarding the equity trade matter of the company's major shareholder with china resources sanjiu medical & pharmaceutical, the company's general manager Cai Jinyong stated that the company and relevant parties are actively promoting the various aspects of this trade.

cls.cnNov 27, 2024 09:29 ET

Tianxin Pharmaceutical's chairman has been placed under coercive measures and resigned as the company's legal representative in June | Quick read announcement

①Tonight, Tianxin Pharmaceutical announced that its actual controller and chairman, Xu Jiangnan, has been detained for investigation; ②In June this year, Xu Jiangnan resigned as the legal representative of the company; ③Since the middle of last year, dozens of pharmaceutical company chairmen and executives have been detained or investigated, and some have been released from detention.

cls.cnNov 1, 2024 10:31 ET

From cspc innovation pharmaceutical to Stone Medicine Innovation, what has changed is not just the R&D expenses.

From active pharmaceutical ingredients to innovative drugs, from focusing on current profits to focusing on product pipeline and cash flow.

wallstreetcnOct 24, 2024 04:25 ET

CSPC Innovation Pharmaceutical's quarterly net profit hits a new low, while G Stone Biosciences burned over four billion yuan in research and development expenses in the first three quarters. Interpretations of the financial report.

①Affected by the lower price of caffeine and the increase in investment in Giant Stone Bioscience, cspc innovation pharmaceutical handed in a third-quarter report with declining performance. ②Q3 of this year also became the worst quarter in terms of the company's profitability up to now. ③After planning for more than 9 months, the acquisition of Stone Pharmaceutical by cspc innovation pharmaceutical finally made new progress last week.

cls.cnOct 23, 2024 09:15 ET

Vitamin price increase dividend realized! zhejiang nhu Q3 net profit increased by nearly 190% year-on-year|interpretations

1. Zhejiang NHU and Zhejiang Garden Biopharmaceutical have seen a sharp increase in profits in Q3; 2. The rise in prices of vitamins has boosted manufacturers' performance; 3. Vitamin prices have declined from their peak, but still remain relatively high; 4. The price hike benefits will continue into Q4, but profit growth may slow down.

cls.cnOct 23, 2024 09:04 ET